179 related articles for article (PubMed ID: 36483433)
21. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review.
van Rossen TM; Ooijevaar RE; Vandenbroucke-Grauls CMJE; Dekkers OM; Kuijper EJ; Keller JJ; van Prehn J
Clin Microbiol Infect; 2022 Mar; 28(3):321-331. PubMed ID: 34655745
[TBL] [Abstract][Full Text] [Related]
22. Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020.
Okafor CM; Clogher P; Olson D; Niccolai L; Hadler J
Emerg Infect Dis; 2023 May; 29(5):877-87. PubMed ID: 37081745
[TBL] [Abstract][Full Text] [Related]
23. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
24. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.
Dinh A; Le Monnier A; Emery C; Alami S; Torreton É; Duburcq A; Barbier F
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1297-1305. PubMed ID: 30941532
[TBL] [Abstract][Full Text] [Related]
25. Prospective Study on Incidence, Risk Factors and Outcome of Recurrent
Granata G; Petrosillo N; Adamoli L; Bartoletti M; Bartoloni A; Basile G; Bassetti M; Bonfanti P; Borromeo R; Ceccarelli G; De Luca AM; Di Bella S; Fossati S; Franceschini E; Gentile I; Giacobbe DR; Giacometti E; Ingrassia F; Lagi F; Lobreglio G; Lombardi A; Lupo LI; Luzzati R; Maraolo AE; Mikulska M; Mondelli MU; Mularoni A; Mussini C; Oliva A; Pandolfo A; Rogati C; Trapani FF; Venditti M; Viale P; Caraffa E; Cataldo MA; On Behalf Of The ReCloDi Recurrence Of Clostridioides Difficile Infection Study Group
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33800334
[TBL] [Abstract][Full Text] [Related]
26. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
27. Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study.
Kuntz JL; Baker JM; Kipnis P; Li SX; Liu V; Xie Y; Marcella S; Escobar GJ
Infect Control Hosp Epidemiol; 2017 Jan; 38(1):45-52. PubMed ID: 27760583
[TBL] [Abstract][Full Text] [Related]
28. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of
Escudero-Sánchez R; Ruíz-Ruizgómez M; Fernández-Fradejas J; García Fernández S; Olmedo Samperio M; Cano Yuste A; Valencia Alijo A; Díaz-Pollán B; Rodríguez Hernández MJ; Merino De Lucas E; Martín Segarra O; Sáez Bejar C; Armiñanzas Castillo C; Gutiérrez Gutiérrez B; Rodríguez-Pardo D; Ramos Martínez A; De La Torre Cisneros J; López-Medrano F; Cobo Reinoso J
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374989
[TBL] [Abstract][Full Text] [Related]
29. Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life.
Hengel RL; Schroeder CP; Jo J; Ritter TE; Nathan RV; Gonzales-Luna AJ; Obi EN; Dillon RJ; Van Anglen LJ; Garey KW
J Patient Rep Outcomes; 2022 May; 6(1):49. PubMed ID: 35567724
[TBL] [Abstract][Full Text] [Related]
30. Bezlotoxumab in Patients with a Primary
Granata G; Schiavone F; Pipitone G
Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358149
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.
Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
BMC Infect Dis; 2014 Jun; 14():306. PubMed ID: 24898123
[TBL] [Abstract][Full Text] [Related]
32. Blockade of T helper 17 cell function ameliorates recurrent Clostridioides difficile infection in mice.
Wang S; Deng W; Li F; Chen YE; Wang PU
Acta Biochim Biophys Sin (Shanghai); 2021 Oct; 53(10):1290-1299. PubMed ID: 34379099
[TBL] [Abstract][Full Text] [Related]
33. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection.
Sheitoyan-Pesant C; Abou Chakra CN; Pépin J; Marcil-Héguy A; Nault V; Valiquette L
Clin Infect Dis; 2016 Mar; 62(5):574-580. PubMed ID: 26582748
[TBL] [Abstract][Full Text] [Related]
34. The burden of CDI in the United States: a multifactorial challenge.
Feuerstadt P; Theriault N; Tillotson G
BMC Infect Dis; 2023 Mar; 23(1):132. PubMed ID: 36882700
[TBL] [Abstract][Full Text] [Related]
35. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
Vitikainen K; Haapamäki J; Färkkilä M; Anttila VJ; Arkkila P
Scand J Gastroenterol; 2018 Aug; 53(8):947-951. PubMed ID: 30041549
[TBL] [Abstract][Full Text] [Related]
36. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
Wilcox MH; Ahir H; Coia JE; Dodgson A; Hopkins S; Llewelyn MJ; Settle C; Mclain-Smith S; Marcella SW
J Antimicrob Chemother; 2017 Sep; 72(9):2647-2656. PubMed ID: 28633368
[TBL] [Abstract][Full Text] [Related]
37. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.
Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA
Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248
[TBL] [Abstract][Full Text] [Related]
38. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study.
Ghosh S; Antunes A; Rinta-Kokko H; Chaparova E; Lay-Flurrie S; Tricotel A; Andersson FL
Int J Infect Dis; 2024 May; 142():106967. PubMed ID: 38368927
[TBL] [Abstract][Full Text] [Related]
39. Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review.
Armstrong EP; Malone DC; Franic DM; Pham SV; Gratie D; Amin A
Infect Dis Ther; 2023 Jul; 12(7):1775-1795. PubMed ID: 37395984
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent
Šamadan L; Jeličić M; Vince A; Papić N
Antibiotics (Basel); 2021 Jun; 10(7):. PubMed ID: 34198964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
